What is Commense?
Commense operates at the intersection of immunology and microbiology, focusing on the critical role of the microbiome in early human development. The company is developing a pipeline of novel therapeutics designed to mitigate the increased risks of allergies, immune disorders, asthma, and obesity associated with C-section births. By leveraging deep insights into human-microbe interactions, Commense aims to restore natural microbial seeding in newborns, effectively mimicking the benefits of natural birth. This scientific approach positions the company as a pioneer in the emerging field of microbiome-based preventative medicine, addressing a significant unmet need in global neonatal care where C-section rates continue to climb.
How much funding has Commense raised?
Commense has raised a total of $40M across 1 funding round:
Series B
$40M
Series B (2017): $40M with participation from Nest Bio, OrbiMed, Fidelity Management & Research Company, and Rock Springs Capital
Key Investors in Commense
Nest Bio
Nest.bio is a research, development, and venture firm focused on transforming breakthrough life sciences and healthcare technologies into revolutionary companies.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
Fidelity Management & Research Company
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, retirement planning, brokerage, and advisory solutions for individual investors, businesses, employers, and institutions.
What's next for Commense?
With this major enterprise-level funding, Commense is poised to transition from foundational research into more advanced clinical development phases. The capital infusion will likely be directed toward scaling its therapeutic pipeline and expanding its intellectual property portfolio. As the company matures, it will focus on validating its microbial seeding protocols through rigorous clinical trials, aiming to establish a new standard of care for infants delivered via C-section. The strategic backing from top-tier healthcare investors provides not only the necessary financial runway but also the operational expertise required to navigate the complex regulatory landscape of biotech innovation. Future growth will likely center on commercializing these therapeutic interventions and integrating them into standard hospital delivery protocols, ultimately aiming to improve long-term health outcomes for a significant portion of the global population.
See full Commense company page
